The hypothesis of the greater efficacy of anakinra in early phases of disease is in line with previous studies which reported increased survival in macrophage activation syndrome following early intervention with IL-1 blockade (Cavalli et al., 2021). The gene discussed is IL1A; the disease is macrophage activation syndrome.